SILINTAN 25/pills — Class I drug recall D-0388-2026
Ongoing recall by ANTHONY TRINH, 123Herbals LLC, reported 2026-03-11, distributed nationwide. Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared meloxicam.
| Recall number | D-0388-2026 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | ANTHONY TRINH, 123Herbals LLC, Rosemead, CA, United States |
| Recall initiated | 2025-10-20 |
| Classified | 2026-03-13 |
| Reported by FDA | 2026-03-11 |
| Distributed | Nationwide (US) |
| Reason classes | undeclared allergen, unapproved product |
Product
SILINTAN 25/pills, packaged in a 25-count bottle, Shanghai Chinese Medical Works, Shanghai, China
Reason for recall
Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared meloxicam.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0388-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.